{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T04:32:23Z","timestamp":1784003543392,"version":"3.55.0"},"reference-count":25,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Background: Peripheral artery disease (PAD) affects over 200 million individuals globally, leading to significant morbidity and mortality. For patients with complex lesions of the superficial femoral artery requiring revascularization, autologous vein bypass surgery remains a viable treatment option. Postoperative anticoagulation is critical for maintaining graft patency, but the optimal choice between direct oral anticoagulants (DOACs) and warfarin remains uncertain. Objectives: This study aims to evaluate the patency of below-the-knee autologous vein bypasses in PAD patients receiving either DOACs or warfarin over a two-year period. Methods: A retrospective cohort study was conducted at a tertiary care hospital in Berlin, Germany, including patients who underwent femoropopliteal or femorocrural bypass surgery between 2017 and 2022. Patients were divided into two groups based on postoperative anticoagulation therapy: DOACs or warfarin. The primary outcome was graft patency at 24 months. Results: Out of 192 patients, after applying exclusion criteria, 36 were analyzed. The mean bypass patency was longer in the warfarin group (18.3 months) compared to the DOAC group (14.3 months). However, the log-rank test p-value (0.524) suggests that this difference is not statistically significant. Given the log-rank test\u2019s limitations in accounting for confounders, a multivariable Cox regression was performed, including age, sex, comorbidities, bypass type and antiplatelet use. The model (Omnibus p = 0.93) showed no statistically significant effect for any variable. Conclusions: DOACs appear to be a viable alternative to warfarin in maintaining graft patency in below-the-knee autologous vein bypasses for PAD patients. The lack of a need for regular INR monitoring with DOACs may offer a practical advantage in clinical settings.<\/jats:p>","DOI":"10.3390\/jpm15070292","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T04:43:37Z","timestamp":1751863417000},"page":"292","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparing the Impact of DOACs and Warfarin on Below-the-Knee Autologous Vein Bypass Patency in Peripheral Artery Disease: A Retrospective Cohort Study with 2-Year Follow-Up"],"prefix":"10.3390","volume":"15","author":[{"given":"Francisca","family":"Frias","sequence":"first","affiliation":[{"name":"Department of Vascular and Endovascular Surgery, Vivantes Hospital Neukoelln, 12351 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0729-2838","authenticated-orcid":false,"given":"G\u00fcnay","family":"Kalender","sequence":"additional","affiliation":[{"name":"Department of Vascular and Endovascular Surgery, Vivantes Hospital Neukoelln, 12351 Berlin, Germany"},{"name":"Science & Research Department, Brandenburg Medical School Theodor Fontane, 16816 Neuruppin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1161\/CIRCRESAHA.116.303849","article-title":"Epidemiology of Peripheral Artery Disease","volume":"116","author":"Criqui","year":"2015","journal-title":"Circ. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e1020","DOI":"10.1016\/S2214-109X(19)30255-4","article-title":"Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: An updated systematic review and analysis","volume":"7","author":"Song","year":"2019","journal-title":"Lancet Glob. Health"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"100947","DOI":"10.1016\/j.cpcardiol.2021.101082","article-title":"Peripheral Artery Disease: A Comprehensive Updated Review","volume":"47","author":"Shamaki","year":"2022","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.atherosclerosis.2018.05.033","article-title":"Update on peripheral artery disease: Epidemiology and evidence-based facts","volume":"275","author":"Shu","year":"2018","journal-title":"Atherosclerosis"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ejvs.2015.10.022","article-title":"The Risk of Disease Progression in Peripheral Arterial Disease is Higher than Expected: A Meta-Analysis of Mortality and Disease Progression in Peripheral Arterial Disease","volume":"51","author":"Sigvant","year":"2016","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ejvs.2017.07.005","article-title":"Amputation Rates, Mortality, and Pre-operative Comorbidities in Patients Revascularised for Intermittent Claudication or Critical Limb Ischaemia: A Population Based Study","volume":"54","author":"Fridh","year":"2017","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"ref_7","first-page":"CD005158","article-title":"Cochrane Heart Group Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events","volume":"2017","author":"Squizzato","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Antithrombotic Trialists\u2019 (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1055\/s-0032-1330232","article-title":"A Review of the Role of Anticoagulation in the Treatment of Peripheral Arterial Disease","volume":"21","author":"Whayne","year":"2012","journal-title":"Int. J. Angiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.jacc.2018.03.008","article-title":"Major Adverse Limb Events and Mortality in Patients with Peripheral Artery Disease: The COMPASS Trial","volume":"71","author":"Anand","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Biscetti, F., Nardella, E., Rando, M.M., Cecchini, A.L., Gasbarrini, A., Massetti, M., and Flex, A. (2021). Outcomes of Lower Extremity Endovascular Revascularization: Potential Predictors and Prevention Strategies. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22042002"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/j.jvs.2015.07.065","article-title":"The natural history of untreated severe or critical limb ischemia","volume":"62","author":"Steffen","year":"2015","journal-title":"J. Vasc. Surg."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jvs.2013.08.003","article-title":"Society for Vascular Surgery Lower Extremity Guidelines Committee. The Society for Vascular Surgery Lower Extremity Threatened Limb Classification System: Risk stratification based on Wound, Ischemia, and foot Infection (WIfI)","volume":"59","author":"Mills","year":"2014","journal-title":"J. Vasc. Surg."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.jvs.2014.08.107","article-title":"An early validation of the Society for Vascular Surgery Lower Extremity Threatened Limb Classification System","volume":"60","author":"Cull","year":"2014","journal-title":"J. Vasc. Surg."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jvs.2015.07.068","article-title":"Bypass surgery versus endovascular interventions in severe or critical limb ischemia","volume":"63","author":"Steffen","year":"2016","journal-title":"J. Vasc. Surg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5S","DOI":"10.1016\/j.jvs.2010.01.073","article-title":"Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: An intention-to-treat analysis of amputation-free and overall survival in patients randomized to a bypass surgery-first or a balloon angioplasty-first revascularization strategy","volume":"51","author":"Bradbury","year":"2010","journal-title":"J. Vasc. Surg."},{"key":"ref_17","first-page":"CD000535","article-title":"Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery","volume":"2023","author":"Forster","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_18","first-page":"CD000536","article-title":"Cochrane Vascular Group Antithrombotic agents for preventing thrombosis after infrainguinal arterial bypass surgery","volume":"2023","author":"Geraghty","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.avsg.2021.07.028","article-title":"A Systematic Review and Meta-Analysis on the Efficacy and Safety of Direct Oral Anticoagulants in Patients with Peripheral Artery Disease","volume":"80","author":"Peppas","year":"2022","journal-title":"Ann. Vasc. Surg."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Pomozi, E., Nagy, R., Feh\u00e9rv\u00e1ri, P., Hegyi, P., Kiss, B., Dembrovszky, F., Kosztin, A., Nardai, S., Zima, E., and Szeberin, Z. (2023). Direct Oral Anticoagulants as the First Choice of Anticoagulation for Patients with Peripheral Artery Disease to Prevent Adverse Vascular Events: A Systematic Review and Meta-Analysis. J. Cardiovasc. Dev. Dis., 10.","DOI":"10.3390\/jcdd10020065"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ejvs.2020.06.016","article-title":"Alternative Venous Conduits for Below Knee Bypass in the Absence of Ipsilateral Great Saphenous Vein","volume":"60","author":"Nierlich","year":"2020","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/1358863X10373299","article-title":"Influence of polyvascular disease on cardiovascular event rates. Insights from the REACH Registry","volume":"15","author":"Zeymer","year":"2010","journal-title":"Vasc. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jvs.2022.06.005","article-title":"Impact of anticoagulation\/antiplatelet therapy on femoropopliteal bypass graft outcomes","volume":"76","author":"Kim","year":"2022","journal-title":"J. Vasc. Surg."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Magnani, G., Denegri, A., Gurgoglione, F.L., Barocelli, F., Indrigo, E., Catellani, D., Signoretta, G., Bettella, A., Tuttolomondo, D., and Solinas, E. (2023). Dual Antiplatelet Therapy or Antiplatelet Plus Anticoagulant Therapy in Patients with Peripheral and Chronic Coronary Artery Disease: An Updated Review. J. Clin. Med., 12.","DOI":"10.20944\/preprints202306.1260.v1"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","article-title":"Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): A randomised, double-blind, placebo-controlled trial","volume":"392","author":"Gaziano","year":"2018","journal-title":"Lancet"}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/15\/7\/292\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:05:39Z","timestamp":1760033139000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/15\/7\/292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":25,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["jpm15070292"],"URL":"https:\/\/doi.org\/10.3390\/jpm15070292","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]}}}